Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants-Reference-Cited by-同舟云学术

Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariants

Published:2022-10 Issue:10 Volume:3 Page:705-721.e11
ISSN:2666-6340
Container-title:Med
language:en
Short-container-title:Med

Author:

Duty J. Andrew,Kraus Thomas,Zhou Heyue,Zhang Yanliang,Shaabani Namir,Yildiz Soner,Du Na,Singh Alok,Miorin Lisa,Li Donghui,Stegman Karen,Ophir Sabrina,Cao Xia,Atanasoff Kristina,Lim Reyna,Mena Ignacio,Bouvier Nicole M.,Kowdle Shreyas,Carreño Juan Manuel,Rivero-Nava Laura,Raskin Ariel,Moreno Elena,Johnson Sachi,Rathnasinghe Raveen,Pai Chin I.,Kehrer Thomas,Cabral Elizabeth Paz,Jangra Sonia,Healy Laura,Singh Gagandeep,Warang Prajakta,Simon Viviana,Sordillo Emilia Mia,van Bakel Harm,Liu Yonghong,Sun Weina,Kerwin Lisa,Teijaro John,Schotsaert Michael,Krammer Florian,Bresson Damien,García-Sastre Adolfo,Fu Yanwen,Lee Benhur,Powers Colin,Moran Thomas,Ji Henry,Tortorella Domenico,Allen Robert^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference60 articles.

1. A novel coronavirus from patients with pneumonia in China, 2019;Zhu;N. Engl. J. Med.,2020

2. Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19);Ahn;J. Microbiol. Biotechnol.,2020

3. SARS-CoV-2 vaccines: status report;Amanat;Immunity,2020

4. SARS-CoV-2 viral variants—tackling a moving target;Mascola;JAMA,2021

5. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic;Hoffmann;Cell,2022

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody;mBio;2024-01-16

2. Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19;Med;2024-01

3. Assessment of safety and intranasal neutralizing antibodies of HPMC-based human anti-SARS-CoV-2 IgG1 nasal spray in healthy volunteers;Scientific Reports;2023-09-20

4. Anin vitroexperimental pipeline to characterize the binding specificity of SARS-CoV-2 neutralizing antibodies;2023-04-21

5. Siglec-9 Restrains Antibody-Dependent Natural Killer Cell Cytotoxicity against SARS-CoV-2;mBio;2023-02-28